Author: Henrik

In the world of investment, as famously stated by Charlie Munger of Berkshire Hathaway, the primary risk isn’t market volatility but the potential for permanent capital loss. This wisdom underscores the importance of analyzing a company’s balance sheet as a critical part of assessing its investment risk, particularly concerning its debt levels. A closer look […]

Following the launch of its Workplace platform aimed at unifying its collaboration solutions, Zoom announced this week that it has outperformed its Q1 2025 earnings expectations and raised its financial outlook for the year. Known for its meteoric rise during the pandemic, Zoom is now solidifying its position in the post-pandemic “Vaccine Economy,” demonstrating the […]

Tesla Inc. (NASDAQ: TSLA) has sparked renewed interest among investors and industry onlookers with its latest update on the development of its electric semitruck, the Tesla Semi. During a presentation at the Advanced Clean Transportation (ACT) Expo in Las Vegas, Tesla executive Dan Priestley provided significant new details about the project, which has been peppered […]

Tesla (TSLA ), a beacon of innovation in the automotive sector, is setting its sights on becoming the world’s leading car manufacturer by 2030, with an ambitious goal to sell 20 million electric vehicles annually. This target not only aims to double the current sales volume of Toyota, the reigning top automaker, but also positions […]

Viking Therapeutics stands at the forefront of exciting clinical developments, with four distinct programs that could potentially transform the landscape of medical treatment for several serious conditions. This biotech firm’s journey through various phases of clinical trials offers a glimpse into what could be a significant breakthrough in both common and rare diseases. Diverse Portfolio […]

In the world of biotechnology, Axsome Therapeutics stands out as a beacon of potential. This company is not just another player in the field; it brings a unique promise that captures the interest of investors and patients alike. Today, let’s dive deep into what makes Axsome a notable entity in the biotech sector, especially for […]

In an innovative stride within the field of obesity treatment, researchers from the University of Copenhagen have pioneered a new type of weight-loss drug that could redefine treatment methodologies. Published in Nature, their research introduces a novel therapeutic approach that not only targets the body but also the brain’s adaptability, referred to as neuroplasticity. A […]

Welcome to the watchlist for Week 21 2024. This weekly compilation offers some ideas for you to analyze. Please note that the trades listed here are not ready-to-execute suggestions; do your own due diligence before trading. I dedicate many hours over the weekend to preparing this list, so instead of sharing it directly with friends, […]

In the ever-evolving landscape of medical science, semaglutide stands out not just as a treatment but as a beacon of potential across various health disciplines. Originally developed for managing type 2 diabetes, this medication has cascaded into other areas of significant health concern, such as obesity, cardiovascular diseases, and potentially, addiction and dementia. This exploration […]

In the dynamic world of biotechnology investments, uncovering gems that promise not only groundbreaking therapeutic benefits but also substantial financial returns is a complex yet rewarding challenge. Viking Therapeutics (NASDAQ:VKTX), a relatively under-the-radar entity, emerges as a compelling narrative in the battle against obesity—a modern health epidemic. A Potent Candidate Emerges At the heart of […]

In the dynamic world of pharmaceuticals, Viking Therapeutics (NASDAQ:VKTX) recently found itself in a precarious position as shares dropped amid announcements from Swiss pharmaceutical giant, Roche (OTCQX:RHHBY). Roche reported a significant 19% average weight loss in a Phase 1 trial of its drug, CT-388, a dual GLP-1/GIP receptor agonist, over a 24-week period in healthy […]

Introduction: Good morning, everyone, and welcome to Flutter’s Q1 2024 results call. With me this morning are Flutter’s CEO, Peter Jackson, and CFO, Paul Edgecliffe-Johnson. After this short intro, Peter will open up with a brief run-through of our good progress during the quarter, and then Paul will take you through the Q1 financials. We […]

In the realm of regional banking, First Horizon National Corporation (FHN) has carved out a distinguished presence. Established in 1864 and headquartered in Memphis, Tennessee, First Horizon has grown from a local bank to a significant financial services company that influences a substantial portion of the southeastern United States. This blog post delves into the […]

In the ever-evolving landscape of technology, the importance of semiconductor equipment cannot be overstated. As devices become increasingly integrated into our daily lives, from smartphones to electric vehicles, the demand for advanced semiconductor technology grows. At the forefront of this industry is Veeco Instruments Inc. (VECO), a company that has carved out a niche in […]

Qualcomm, a leader in wireless chip technology, recently reported mixed financial results for its fiscal third quarter and provided a less-than-optimistic forecast for the upcoming quarter. This news led to a significant drop in Qualcomm’s stock price. In the quarter ending June 25, Qualcomm reported adjusted earnings of $1.87 per share on sales of $8.45 […]

In the dynamic world of investing, momentum strategies offer a compelling route for capitalizing on market trends. Momentum investing hinges on the principle of capturing gains by riding ‘hot’ stocks—those whose prices are exhibiting strong upward trends. The core philosophy is simple yet powerful: buy stocks that are performing well now in the hope that […]

Salesforce (CRM) continues to impress the market with its robust performance and promising growth trajectory, earning a strong Buy rating from Bank of America Securities analyst Bradley Sills, who has set a price target of $360.00. This endorsement is grounded in several key factors that highlight the company’s operational excellence and potential for further expansion. […]